Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World

Purpose: Interest in leveraging real-world evidence (RWE) to support regulatory decision making for product effectiveness has been increasing globally as evident by the increasing number of regulatory frameworks and guidance documents. However, acceptance of RWE, especially before marketing for regulatory approval, differs across countries. In addition, guidance on the design and conduct of innovative clinical trials, such as randomized controlled registry studies, pragmatic trials, and other hybrid studies, is lacking. Methods: We assessed the global regulatory environment with regard to RWE based on regional availability of the following 3 key regulatory elements: (1) RWE regulatory framework, (2) data quality and standards guidance. and (3) study methods guidance. Findings: This article reviews the available frameworks and existing guidance from across the globe and discusses the observed gaps and opportunities for further development and harmonization. (C) 2022 The Author(s). Published by Elsevier Inc.

Automated summary

This article reviews the current global regulatory environment regarding real-world evidence (RWE), including differences in regulatory frameworks, data quality guidance, and study methods guidance across countries. It also highlights opportunities for further development and harmonization.